Fimbriae 2/3, Recombinant, B. pertussis (FHA)
Catalog No : USB-208898
644.85€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | Fimbriae 2/3, Recombinant, B. pertussis (FHA) | ||
|---|---|---|---|
| Catalog No | USB-208898 | ||
| Supplier’s Catalog No | 208898 | ||
| Supplier | US Biologicals | ||
| Source antigen | Recombinant | ||
| Reactivity | |||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | 22 | ||
| Storage | -20°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Highly Purified | ||
| Purity | Highly Purified (~99%) | ||
| Form | Supplied as a liquid in 0.05M Tris, pH 8, 0.15M sodium chloride. | ||
| Reactivity life | 12 months | ||
| Note | For reserch purpose only | ||
| Purity | Highly Purified (~99%) | ||
| Description | Bordetella pertussis causes whooping cough, a highly communicable disease which continues to be a public health concern despite high levels of vaccination with either whole-cell or acellular pertussis vaccines. In the last decade, a resurgence of pertussis. B. pertussis vaccine was first developed in 1920 using whole bacterium. In 1942, the whole-cell pertussis vaccine was combined with diphtheria and tetanus toxoids to generate the first DTP combination vaccine. Whole cell vaccines have some side effects. Acellular pertussis vaccines contain between one and five B. pertussis antigens: pertussis toxin (Ptx),filamentous hemagglutinin (FHA), pertactin (Prn), and fimbriae (Fim2 and Fim3). Many aspects of the pathogenesis of pertussis and vaccine correlates of protection are poorly understood. However, antibodies to Prn, Fim, and, to a lesser extent, Ptx appear to have a direct correlation with protection. Fimbriae have been considered important vaccine components for many years in both whole-cell and acellular vaccines. B. pertussis expresses two serologically distinct fimbriae composed of either Fim2 (207aa) or Fim3 (204aa) major subunits which have molecular weights of 22,500 (207aa) and 22,000, respectively. Antibody responses to Fim1-3 have been observed in human samples. Source: Recombinant protein corresponding to B. pertussis Fimbrae 2/3. Molecular Weight: ~22kD Reactivity: Fim2/3 reacts with human serem vaccinated with pertussis vaccine. Applications: Suitable for use in ELISA, Western Blot, Antibody Titration or Control protein for Pertussis vaccines. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 6 months after receipt at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. | ||
Product Details
© 2020 Imugex All Rights Reserved